Effectiveness of Low-Dose Indinavir/Ritonavir at 400/100 mg Twice a Day With 2 Nucleoside Reverse Transcriptase Inhibitors in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-Infected Patients in India

This publication has 10 references indexed in Scilit:

• Pharmacokinetics of Reduced-Dose Indinavir/Ritonavir 400/100 Mg Twice Daily in HIV-1-Infected Thai Patients
  Antiviral Therapy, 2005
• Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice daily
  HIV Medicine, 2005
• Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.
  HIV Medicine, 2003
• A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy
  Clinical Infectious Diseases, 2003
• Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
  AIDS, 2003
• Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients
  AIDS, 2003
• Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 100-mg Regimen in Protease Inhibitor–Naive HIV-Infected Adults
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
• First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results
  HIV Medicine, 2002
• High Indinavir Cmin Is Associated With Higher Toxicity in Patients on Indinavir-Ritonavir 800/100 mg Twice-Daily Regimen
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
• Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
  AIDS, 1999